Development of the polymer micelle carrier system for doxorubicin.
We show the result of pre-clinical study of NK911, a polymeric micelle carrier system for doxorubicin (DOX). The NK911 micelle carrier consists of polyethyleneglycol and conjugated doxorubicin-polyaspartic acid. It has high hydrophobic inner core, and therefore can entrap the sufficient amount of DOX. NK911 has a small particle size of about 40 nm in diameter that accumulates in tumor tissue by EPR effect showing much stronger activity than the free DOX. We plan to perform a clinical trial at National Cancer Center Hospital, Japan from 2001.
Nakanishi
T
T
Drug Research Department, Nippon Kayaku Co., Ltd., 3-31-12 Shimo, Kita-ku, 115-8588, Tokyo, Japan. takeshi.nakanishi@nipponkayaku.co.jp
Fukushima
S
S
Okamoto
K
K
Suzuki
M
M
Matsumura
Y
Y
Yokoyama
M
M
Okano
T
T
Sakurai
Y
Y
Kataoka
K
K
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004317:Doxorubicin / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology; D004337:Drug Carriers; D004355:Drug Stability; D006801:Humans; D051379:Mice; D008823:Micelles; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010316:Particle Size; D010455:Peptides / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D011108:Polymers; D014407:Tumor Cells, Cultured
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008823:Micelles; C438847:NK911; D010455:Peptides; D011108:Polymers; D011092:Polyethylene Glycols; D004317:Doxorubicin